ArticleFrontiers in nutrition2025
The non-high-density lipoprotein cholesterol to high-density lipoprotein cholesterol ratio is associated with early onset type 2 diabetes with NAFLD: a cross-sectional study in China.
Article in Frontiers in nutrition, 2025. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 1 paper.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
1 citing paper in PubMed.
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
9 authors.
Funding
No grant is acknowledged in the PubMed record.
Abstract
Background: The non-high-density lipoprotein cholesterol to high-density lipoprotein cholesterol ratio (NHHR) is a novel composite lipid biomarker associated with metabolic diseases. This study aims to explore the potential relationship between early-onset type 2 diabetes mellitus combined with NAFLD and NHHR. Methods: A total of 1,158 patients with type 2 diabetes were enrolled and categorized by age at onset into the early-onset type 2 diabetes (EOT2D) group (260 cases, <40 years) and the late-onset type 2 diabetes (LOT2D) group (898 cases, ≥40 years). The EOT2D group was further subdivided into those with NAFLD (136 cases) and those without NAFLD (124 cases). Multivariate logistic regression assessed the association between NHHR and EOT2D, as well as EOT2D combined with NAFLD. Additionally, we employed subgroup analysis, interaction analysis, smoothing curve fitting, and receiver operating characteristic curve analysis to further explore risk factors for EOT2D and EOT2D combined with NAFLD. Results: This cross-sectional study included 260 EOT2D patients and 898 LOT2D patients. After adjusting for confounding factors, the study found that for every 1-unit increase in NHHR, the risk of EOT2D increased by 22% (OR = 1.22, 95% CI: 1.05-1.42), and the risk of EOT2D with NAFLD increased by 41% (OR = 1.41, 95% CI: 1.01-1.98). The AUC for diagnosing EOT2D with NAFLD using NHHR was 0.658 (95% CI: 0.592-0.724), with an optimal cutoff of 3.105 (sensitivity 77.21%, specificity 50.00%). Conclusion: Our study suggests that NHHR is a risk factor for EOT2D and EOT2D combined with NAFLD, serving as a reference indicator for screening this high-risk population.
Indexed as
Identifiers
What Socratic holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the Socratic graph.